'Is This Program Right for Me?' How a GLP-1 or Peptide Clinic Should Handle the First Call
A caller has spent a month reading about semaglutide, tirzepatide, or a peptide protocol, and finally phones your longevity clinic. Her first real question is not about price. It is whether a program is right for her at all, and whether she can start without coming in. A vague answer at the desk sends a ready buyer to the next clinic.
Ed
GLP-1, peptides, telehealth, first call, longevity clinic
A caller has been reading about GLP-1 medications and peptide protocols for a month. She has watched the videos, read the forums, and decided she wants to try. When she finally phones your longevity clinic, her first real question is not what it costs. It is quieter and more decisive than that: is this right for me, and can I do this without coming in for a visit. How your front desk fields that question determines whether a person who has already talked herself into starting starts with you, or with whoever answers the phone more usefully next.
This is the "is it right for me" caller. She is at the top of the buying curve, she is easy to lose, and she is lost most often not to a competitor with better medicine but to a front desk that could not tell her anything and did not book her anything.
General information, not medical advice. Eligibility is a clinical determination made by a licensed clinician.
What the clinician will review (not the front desk)
The desk cannot and must not diagnose, and it does not collect any of the following. This is what a licensed clinician reviews at the consultation, which is why the consultation comes first.
The baseline thresholds. FDA-approved GLP-1 therapy for chronic weight management generally starts at a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. Most telehealth-based programs follow the same frame.
The comorbidities clinicians weigh. Recognized comorbidities commonly include type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, and cardiovascular disease, with some programs also weighing fatty liver disease, osteoarthritis, and polycystic ovary syndrome.
The hard stops. A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 is a contraindication. This is a clinician judgment, not a desk judgment, made at the consultation.
The telehealth reality. Licensed clinicians can evaluate and prescribe remotely after an appropriate clinical assessment. On the supply side, after the FDA declared the semaglutide shortage resolved on February 21, 2025, 503A compounding of a copy of an approved GLP-1 is tightly limited by FDA (generally no more than four prescriptions a month of an "essentially a copy" product), so most patients are on branded medication.
Why the "is it right for me" question is a booking, not an FAQ
The caller asking whether it is right for her is not asking for a diagnosis. She is asking for permission to hope this will work for her, and for a path to find out. When the desk answers with a version of you will have to ask the provider and offers nothing else, it strands the most motivated caller of the day between wanting to start and knowing how. She does not wait. She calls the next name on her list.
Part of the difficulty is that these callers often cannot name what they want precisely, which is the same intake-translation problem covered in the caller who cannot name the program she is asking for. And the value of getting the first response right is compounded by what happens after month three, the retention cliff detailed in the GLP-1 clinic retention cliff: a caller lost at hello never reaches the point where the program actually pays off.
What a compliant intake does with "is this right for me"
A front desk built for this vertical treats the question as a booking task with four moves, none of which cross into clinical advice.
Capture the basics, nothing clinical. The intake takes contact details and the caller's stated interest in her own words, without asking about weight, conditions or history, and without telling her whether a program fits.
Set the telehealth expectation. Tell her plainly that whether a program fits is decided only by a licensed clinician in a consultation, which can often be done remotely, so she knows the next step is real and near, not a hurdle.
Disclose honestly. If an automated assistant is taking the call, it should identify itself as AI and offer a person on request. In a program a caller will be on for months, the relationship starts with that honesty.
Book the consultation and connect it to the whole program. A GLP-1 or peptide start is the front door to a longer arc of care, the cross-service cadence described in how a biohacking clinic sequences services over time, and the re-engagement economics in the GLP-1 compounding cliff. Re-engagement and service-promotion outreach runs only for patients with documented marketing consent and authorization; TTR never performs cold outreach.
A count you can run this week
We are not going to put a figure on what this costs your clinic. We have not measured your clinic, and a number we modeled is not a number you can act on.
Here is one you can get from your own phone log instead. Pull last month's inbound calls, count the ones where the caller asked some version of "is this right for me," and count how many of those have a booked consultation against them. The gap between those two numbers is yours, and it is real.
The structural point stands on its own: this caller is the highest-intent person who will phone all week, and she is the one a thin front desk is most likely to lose. Seeing that gap on a specific practice's line is what The Line Audit is for.
References
Telehealth GLP-1 eligibility guides (TeleHealthAlly, Middleway Nutrition, TrimRX), 2026: BMI thresholds of 30, or 27 with a comorbidity, and recognized comorbidities.
FDA labeling on GLP-1 contraindications (medullary thyroid carcinoma, MEN type 2); telehealth prescribing after clinical assessment.
MedSpa Standards and industry coverage, 2026: branded prescribing and 503A patient-specific compounding after the FDA declared the semaglutide shortage resolved on February 21, 2025.
Zero-Miss Intake is the name of a design goal, not a guarantee that every call will be answered.
Next Step
If your premium practice runs more than 100 inbound consult inquiries a month and has no structured measurement of how many never reach a scheduled consultation, your pipeline may be leaking revenue you cannot see. The Line Audit shows you what actually happens: we call your line at the hours you're least likely to answer and send you the recordings with a written breakdown.
Audit Real-Time Conversational Velocity: Talk to Rosey, our AI receptionist, at +1 (720) 776-1664 (an AI demo line; calls are recorded).
